Elizabeth Vera-Bolanos1, Kenneth Aldape1, Ying Yuan1, Jimin Wu1, Khalida Wani1, Mary Jo Necesito-Reyes1, Howard Colman1, Girish Dhall1, Frank S Lieberman1, Philippe Metellus1, Tom Mikkelsen1, Antonio Omuro1, Sonia Partap1, Michael Prados1, H Ian Robins1, Riccardo Soffietti1, Jing Wu1, Mark R Gilbert1, Terri S Armstrong1. 1. Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas (E.V.-B., M.R.G.); Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (K.A., K.W.); Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (Y.Y., J.W.); Office of Multicenter Clinical Research, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (M.J.N.-R.); Department of Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah (H.C.); Division of Hematology-Oncology, Children's Hospital Los Angeles, Los Angeles, California (G.D.); Departments of Neurology and Medicine (Medical Oncology), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (F.S.L.); Department of Neurosurgery, Assistance Publique-Hopitaux de Marseille, Aix-Marseille University, Marseille, France (P.M.); Departments of Neurology & Neurosurgery, Henry Ford Hospital, Detroit, Michigan (T.M.); Department of Neurology, Memorial-Sloan Kettering Cancer Center, New York, New York (A.O.); Department of Neurology, Stanford University & Lucile Packard Children's Hospital, Palo Alto, California (S.P.); Department of Neuro-Oncology, UCSF Helen Diller Comprehensive Cancer Center, San Francisco, California (M.P.); Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin (H.I.R.); Department of Neuroscience, University San Giovanni Battista Hospital, Turin, Italy (R.S.); Department of Neurosurgery, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina (J.W.); Department of Family Health, School of Nursing, The University of Texas Health Science Center-Houston, Houston, Texas (T.S.A.); CERN Foundation, Dayton, Ohio.
Abstract
BACKGROUND: Ependymomas are rare CNS tumors. Previous studies describing the clinical course of ependymoma patients were restricted to small sample sizes, often with patients at a specific institution. METHODS: Clinically annotated ependymoma tissue samples from 19 institutions were centrally reviewed. Patients were all adults aged 18 years or older at the time of diagnosis. Potential prognostic clinical factors identified on univariate analysis were included in a multivariate Cox proportional hazards model with backwards selection to model progression-free survival. RESULTS: The 282 adult ependymoma patients were equally male and female with a mean age of 43 years (range, 18-80y) at diagnosis. The majority were grade II (78%) with the tumor grade for 20 cases being reclassified on central review (half to higher grade). Tumor locations were spine (46%), infratentorial (35%), and supratentorial (19%). Tumor recurrence occurred in 26% (n = 74) of patients with a median time to progression of 14 years. A multivariate Cox proportional hazards model identified supratentorial location (P < .01), grade III (anaplastic; P < .01), and subtotal resection, followed or not by radiation (P < .01), as significantly increasing risk of early progression. CONCLUSIONS: We report findings from an ongoing, multicenter collaboration from a collection of clinically annotated adult ependymoma tumor samples demonstrating distinct predictors of progression-free survival. This unique resource provides the opportunity to better define the clinical course of ependymoma for clinical and translational studies.
BACKGROUND:Ependymomas are rare CNS tumors. Previous studies describing the clinical course of ependymomapatients were restricted to small sample sizes, often with patients at a specific institution. METHODS: Clinically annotated ependymoma tissue samples from 19 institutions were centrally reviewed. Patients were all adults aged 18 years or older at the time of diagnosis. Potential prognostic clinical factors identified on univariate analysis were included in a multivariate Cox proportional hazards model with backwards selection to model progression-free survival. RESULTS: The 282 adult ependymomapatients were equally male and female with a mean age of 43 years (range, 18-80y) at diagnosis. The majority were grade II (78%) with the tumor grade for 20 cases being reclassified on central review (half to higher grade). Tumor locations were spine (46%), infratentorial (35%), and supratentorial (19%). Tumor recurrence occurred in 26% (n = 74) of patients with a median time to progression of 14 years. A multivariate Cox proportional hazards model identified supratentorial location (P < .01), grade III (anaplastic; P < .01), and subtotal resection, followed or not by radiation (P < .01), as significantly increasing risk of early progression. CONCLUSIONS: We report findings from an ongoing, multicenter collaboration from a collection of clinically annotated adult ependymoma tumor samples demonstrating distinct predictors of progression-free survival. This unique resource provides the opportunity to better define the clinical course of ependymoma for clinical and translational studies.
Authors: Ayal A Aizer; Marek Ancukiewicz; Paul L Nguyen; Shannon M Macdonald; Torunn I Yock; Nancy J Tarbell; Helen A Shih; Jay S Loeffler; Kevin S Oh Journal: J Neurooncol Date: 2013-09-21 Impact factor: 4.130
Authors: S C Mack; H Witt; R M Piro; L Gu; S Zuyderduyn; A M Stütz; X Wang; M Gallo; L Garzia; K Zayne; X Zhang; V Ramaswamy; N Jäger; D T W Jones; M Sill; T J Pugh; M Ryzhova; K M Wani; D J H Shih; R Head; M Remke; S D Bailey; T Zichner; C C Faria; M Barszczyk; S Stark; H Seker-Cin; S Hutter; P Johann; S Bender; V Hovestadt; T Tzaridis; A M Dubuc; P A Northcott; J Peacock; K C Bertrand; S Agnihotri; F M G Cavalli; I Clarke; K Nethery-Brokx; C L Creasy; S K Verma; J Koster; X Wu; Y Yao; T Milde; P Sin-Chan; J Zuccaro; L Lau; S Pereira; P Castelo-Branco; M Hirst; M A Marra; S S Roberts; D Fults; L Massimi; Y J Cho; T Van Meter; W Grajkowska; B Lach; A E Kulozik; A von Deimling; O Witt; S W Scherer; X Fan; K M Muraszko; M Kool; S L Pomeroy; N Gupta; J Phillips; A Huang; U Tabori; C Hawkins; D Malkin; P N Kongkham; W A Weiss; N Jabado; J T Rutka; E Bouffet; J O Korbel; M Lupien; K D Aldape; G D Bader; R Eils; P Lichter; P B Dirks; S M Pfister; A Korshunov; M D Taylor Journal: Nature Date: 2014-02-19 Impact factor: 49.962
Authors: Aditya Raghunathan; Khalida Wani; Terri S Armstrong; Elizabeth Vera-Bolanos; Maryam Fouladi; Richard Gilbertson; Amar Gajjar; Stewart Goldman; Norman L Lehman; Phillipe Metellus; Tom Mikkelsen; Mary Jo T Necesito-Reyes; Antonio Omuro; Roger J Packer; Sonia Partap; Ian F Pollack; Michael D Prados; H Ian Robins; Riccardo Soffietti; Jing Wu; C Ryan Miller; Mark R Gilbert; Kenneth D Aldape Journal: Brain Pathol Date: 2013-03-28 Impact factor: 6.508
Authors: Stephan Dützmann; Bawarjan Schatlo; Alexander Lobrinus; Michael Murek; Maria Wostrack; Carolin Weiss; Karl Schaller; Andreas Raabe; Bernhard Meyer; Roland Goldbrunner; Kea Franz; Volker Seifert; Christian Senft Journal: J Neurooncol Date: 2013-06-29 Impact factor: 4.130
Authors: Amol J Ghia; Anita Mahajan; Pamela K Allen; Terri S Armstrong; Frederick F Lang; Mark R Gilbert; Paul D Brown Journal: J Neurooncol Date: 2013-10-02 Impact factor: 4.130
Authors: Lindsey M Hoffman; Andrew M Donson; Ichiro Nakachi; Andrea M Griesinger; Diane K Birks; Vladimir Amani; Molly S Hemenway; Arthur K Liu; Michael Wang; Todd C Hankinson; Michael H Handler; Nicholas K Foreman Journal: Acta Neuropathol Date: 2013-11-17 Impact factor: 17.088
Authors: Matthew Parker; Kumarasamypet M Mohankumar; Chandanamali Punchihewa; Ricardo Weinlich; James D Dalton; Yongjin Li; Ryan Lee; Ruth G Tatevossian; Timothy N Phoenix; Radhika Thiruvenkatam; Elsie White; Bo Tang; Wilda Orisme; Kirti Gupta; Michael Rusch; Xiang Chen; Yuxin Li; Panduka Nagahawhatte; Erin Hedlund; David Finkelstein; Gang Wu; Sheila Shurtleff; John Easton; Kristy Boggs; Donald Yergeau; Bhavin Vadodaria; Heather L Mulder; Jared Becksfort; Jared Becksford; Pankaj Gupta; Robert Huether; Jing Ma; Guangchun Song; Amar Gajjar; Thomas Merchant; Frederick Boop; Amy A Smith; Li Ding; Charles Lu; Kerri Ochoa; David Zhao; Robert S Fulton; Lucinda L Fulton; Elaine R Mardis; Richard K Wilson; James R Downing; Douglas R Green; Jinghui Zhang; David W Ellison; Richard J Gilbertson Journal: Nature Date: 2014-02-19 Impact factor: 49.962
Authors: Pooja Panwalkar; Jonathan Clark; Vijay Ramaswamy; Debra Hawes; Fusheng Yang; Christopher Dunham; Stephen Yip; Juliette Hukin; Yilun Sun; Matthew J Schipper; Lukas Chavez; Ashley Margol; Melike Pekmezci; Chan Chung; Adam Banda; Jill M Bayliss; Sarah J Curry; Mariarita Santi; Fausto J Rodriguez; Matija Snuderl; Matthias A Karajannis; Amanda M Saratsis; Craig M Horbinski; Anne-Sophie Carret; Beverly Wilson; Donna Johnston; Lucie Lafay-Cousin; Shayna Zelcer; David Eisenstat; Marianna Silva; Katrin Scheinemann; Nada Jabado; P Daniel McNeely; Marcel Kool; Stefan M Pfister; Michael D Taylor; Cynthia Hawkins; Andrey Korshunov; Alexander R Judkins; Sriram Venneti Journal: Acta Neuropathol Date: 2017-07-21 Impact factor: 17.088
Authors: Rupesh Kotecha; Minesh P Mehta; Eric L Chang; Paul D Brown; John H Suh; Simon S Lo; Sunit Das; Haider H Samawi; Julia Keith; James Perry; Arjun Sahgal Journal: Neuro Oncol Date: 2019-06-10 Impact factor: 12.300
Authors: Muhammad M Abd-El-Barr; Kevin T Huang; Ziev B Moses; J Bryan Iorgulescu; John H Chi Journal: Neuro Oncol Date: 2018-05-18 Impact factor: 12.300